MX2023015271A - Tratamiento para la dismininución de la densidad mineral ósea con inhibidores del integrante 5b de la familia wnt (wnt5b). - Google Patents
Tratamiento para la dismininución de la densidad mineral ósea con inhibidores del integrante 5b de la familia wnt (wnt5b).Info
- Publication number
- MX2023015271A MX2023015271A MX2023015271A MX2023015271A MX2023015271A MX 2023015271 A MX2023015271 A MX 2023015271A MX 2023015271 A MX2023015271 A MX 2023015271A MX 2023015271 A MX2023015271 A MX 2023015271A MX 2023015271 A MX2023015271 A MX 2023015271A
- Authority
- MX
- Mexico
- Prior art keywords
- bone mineral
- mineral density
- wnt5b
- decreased bone
- family member
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218209P | 2021-07-02 | 2021-07-02 | |
| PCT/US2022/035846 WO2023278787A2 (en) | 2021-07-02 | 2022-06-30 | Treatment of decreased bone mineral density with wnt family member 5b (wnt5b) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023015271A true MX2023015271A (es) | 2024-06-11 |
Family
ID=82839088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023015271A MX2023015271A (es) | 2021-07-02 | 2022-06-30 | Tratamiento para la dismininución de la densidad mineral ósea con inhibidores del integrante 5b de la familia wnt (wnt5b). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230083558A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4363586A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024524388A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240043753A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117940565A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022302084A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3225083A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309644A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023015271A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023278787A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090047276A1 (en) * | 2007-05-15 | 2009-02-19 | University Of Washington | Methods for increasing cell or tissue regeneration in a vertebrate subject |
| WO2017023973A1 (en) * | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
-
2022
- 2022-06-30 IL IL309644A patent/IL309644A/en unknown
- 2022-06-30 WO PCT/US2022/035846 patent/WO2023278787A2/en not_active Ceased
- 2022-06-30 CA CA3225083A patent/CA3225083A1/en active Pending
- 2022-06-30 KR KR1020247003957A patent/KR20240043753A/ko active Pending
- 2022-06-30 JP JP2023580537A patent/JP2024524388A/ja active Pending
- 2022-06-30 AU AU2022302084A patent/AU2022302084A1/en active Pending
- 2022-06-30 EP EP22751500.4A patent/EP4363586A2/en active Pending
- 2022-06-30 MX MX2023015271A patent/MX2023015271A/es unknown
- 2022-06-30 CN CN202280057220.0A patent/CN117940565A/zh active Pending
- 2022-06-30 US US17/855,466 patent/US20230083558A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023278787A2 (en) | 2023-01-05 |
| JP2024524388A (ja) | 2024-07-05 |
| KR20240043753A (ko) | 2024-04-03 |
| US20230083558A1 (en) | 2023-03-16 |
| CA3225083A1 (en) | 2023-01-05 |
| WO2023278787A9 (en) | 2024-05-10 |
| AU2022302084A1 (en) | 2024-01-04 |
| CN117940565A (zh) | 2024-04-26 |
| EP4363586A2 (en) | 2024-05-08 |
| IL309644A (en) | 2024-02-01 |
| WO2023278787A3 (en) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023020182A2 (pt) | Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula | |
| WO2020154268A3 (en) | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors | |
| MX2020000604A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| PH12019501942A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| MX2022016458A (es) | Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75). | |
| MX2019010958A (es) | Metodos de tratamiento de tumores. | |
| MX2022002244A (es) | Metodo para identificar respondedores a degradantes de smarca2/4. | |
| PH12019502710A1 (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| WO2017214373A8 (en) | Diagnostic and therapeutic methods for cancer | |
| MX2025004103A (es) | Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa | |
| WO2019241730A3 (en) | Increasing immune activity through modulation of postcellular signaling factors | |
| BR112017012287A2 (pt) | uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr | |
| ZA202301267B (en) | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms | |
| MX2022014254A (es) | Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis. | |
| WO2023278787A3 (en) | Treatment of decreased bone mineral density with wnt family member 5b (wnt5b) inhibitors | |
| PH12021552342A1 (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| EA202192176A1 (ru) | Нарушения, опосредованные интерфероном i типа | |
| AU2020225197A8 (en) | Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof | |
| EA201891693A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови | |
| WO2020190608A3 (en) | Treatment of hyperglycemia with solute carrier family 39 member 5 (slc39a5) inhibitors | |
| MX2023014586A (es) | Tratamiento de la psoriasis con inhibidores del dominio c de la helicasa inducida por interferon 1 (ifih1). | |
| BR112022010310A2 (pt) | Métodos relacionados com a toxicidade e resposta associada com terapia celular para tratamento de malignidades de célula b | |
| WO2020139830A3 (en) | Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors | |
| Wasuworawong et al. | Comparative proteomic analysis of human cholangiocarcinoma cell lines: S100A2 as a potential candidate protein inducer of invasion | |
| GB2569932A (en) | Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment |